SCHEMBL30989944

SCHEMBL30989944

COc1ncc(F)cc1C(=O)NCc1cccc(F)c1F

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MET P08581 1/20 0.52
▸ PDE10A Q9Y233 1/20 0.51
▸ LMNA P02545 2/20 0.47
▸ PTGER4 P35408 1/20 0.45
▸ MAOB P27338 1/20 0.44
▸ RIPK1 Q13546 4/20 0.43
▸ PLA2G1B P04054 1/20 0.43
▸ ATG4B Q9Y4P1 1/20 0.43
▸ MAPT P10636 1/20 0.43
▸ MAPK8 P45983 1/20 0.43
▸ ROCK2 O75116 1/20 0.42
▸ ROCK1 Q13464 1/20 0.42
▸ CHRM4 P08173 1/20 0.42
▸ MEN1 O00255 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ HPGD P15428 2/20 0.41
▸ KCNK3 O14649 1/20 0.41
▸ KCNK5 O95279 1/20 0.41
▸ KCNA5 P22460 1/20 0.41
▸ KCNK17 Q96T54 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30990019 0.91 LMNA (0.57) PDE10ALMNAPTGER4PLA2G1BATG4B
SCHEMBL30990047 0.89 MET (0.51) METPDE10ALMNAPTGER4MAOB
SCHEMBL30989996 0.84 MET (0.53) METPDE10ALMNAPTGER4MAOB
SCHEMBL30989911 0.81 RIPK1 (0.46) LMNAPTGER4RIPK1PLA2G1BATG4B
SCHEMBL30989879 0.80 LMNA (0.55) PDE10ALMNAPTGER4RIPK1MAPT
SCHEMBL30989781 0.79 RIPK1 (0.46) LMNARIPK1MAPTMEN1KMT2A
SCHEMBL922929 0.78 MET (0.53) METPDE10APLA2G1BATG4BROCK2
SCHEMBL30989888 0.76 ROCK2 (0.53) METPDE10APTGER4RIPK1ROCK2
SCHEMBL30989895 0.74 KCNA5 (0.52) METPDE10APTGER4RIPK1ROCK2
SCHEMBL30989915 0.74 LMNA (0.80) LMNAMAPTMAPK8MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4612131-A1 NICOTINAMIDE DERIVATIVES FOR USE IN TREATING DISORDERS ASSOCIATED WITH KCNK13 ACTIVITY Cerevance, Inc. (US) 2025-09-10 — — EP disclosed
WO-2024095003-A1 NICOTINAMIDE DERIVATIVES FOR USE IN TREATING DISORDERS ASSOCIATED WITH KCNK13 ACTIVITY Cerevance, Inc. (US) 2024-05-10 — — WO disclosed
Send feedback